Appearing:
World Orphan Drug Congress Day 2 Wednesday 30th November 2011
9am
Chairman’s opening remarks
Hans Schikan,
CEO,
Prosensa
9.35am
Achieving the clinical added value required for approval
- The very nature of rare diseases creates clinical challenges for orphan drug developers
- How can minimal yet robust clinical data lead to market approval quickly?
- Partnerships in the development stage to enhance success
- How can clinical phases be carried out to accommodate payers and sponsors concerns?
Hans Schikan,
CEO,
Prosensa